nonoxynol-9
Trade name: Delfen
Approved
Dec 10, 1963
Nonoxynol-9, is an organic compound that is used as a surfactant and vaginal spermicide used for contraception in spermicidal creams, jellies, foams, gel, and lubricants. It is also used in conjuction with other methods of contraception, including condoms, cervical caps and diaphragms. Nonoxynol-9 interacts with the lipids in the membranes of the acrosome and the midpiece of the sperm. The sperm membranes are lysed; the acrosome, neck and midpiece of the spermatozoa are loosened and then detached which results in their immobilization and death. Nonoxynol-9 offers no protection against sexually transmitted infections such as gonorrhoea, chlamydia and does not prevent HIV infection and may even favour infection if used frequently. A possible reason, is that nonoxynol-9 can disrupt the epithelium, or wall, of the vagina, thereby potentially facilitating invasion by an infective organism and virus. Nonoxynol-9 and related compounds are ingredients in various cleaning and cosmetic products. — NCATS
Clinical trial activity
11 trials · 15 clinical orgs · 2 marketing orgs
Earliest trial started Nov 2, 1999 (NCT00000929)
Timeline
1960s
- Dec 10, 1963
Personal Products — Earliest FDA Approval
- Dec 10, 1963
Personal Products — NDA Secondary Org
- Dec 10, 1963
Personal Products — NDA Organization
1980s
- Apr 1, 1983
Mayer Laboratories — NDA Secondary Org
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Cell membraneDISRUPTING AGENT
Cell membrane disrupting agent
- Sperm acrosome-associated protein 9INHIBITOR
SPACA9 inhibitor
Approval history
- approvedDec 10, 1963
Chemistry & pharmacology
SMILES
CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1- Mol. weight
- 616.83 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaNonoxynol-9 ↗
- NCATS48Q180SH9T ↗
- ChEMBLCHEMBL2108472 ↗
- ChEMBLCHEMBL1410 ↗
Also known as
- 26-(nonylphenoxy)-3,6,9,12,15,18,21,24-octaoxahexacosan-1-ol
- 26-(nonylphenoxy)-3,6,9,12,15,18,21,24-octaoxahexacosan-1-ol
- c-film
- c-film
- conceptrol
- conceptrol
- delfen
- delfen
- delfen
- double check
- duragel
- duragel
- emko
- emko
- gygel
- gynol 11
- gynol ii
- gynol ii
- intercept
- intercept
- nonaethylene glycol mono(nonylphenyl) ether
- nonaethylene glycol mono(nonylphenyl) ether
- nonaethylene glycol nonylphenyl ether
- nonaethylene glycol nonylphenyl ether
- nonoxinol
- nonoxinol
- nonoxinol
- nonoxinol
- nonoxinol
- nonoxinol 9
- nonoxinol 9
- nonoxynol
- nonoxynol
- nonoxynol 4,9,15,30
- nonoxynol 9
- nonoxynol 9
- nonoxynol 9
- nonoxynol 9
- nonoxynol-9
- nonoxynol-9
- nonoxynol-9
- nonoxynol-9
- nonoxynol-9
- nonoxynol-9
- nonoxynol-9
- nonoxynol-9
- nonylphenol octa(oxyethylene) ethanol
- nonylphenol octa(oxyethylene) ethanol
- nonylphenoxypolyethoxyethanol
- nonylphenoxypolyethoxyethanol
- ortho-creme
- ortho-creme
- ortho-forms
- peg-9 nonyl phenyl ether
- peg-9 nonyl phenyl ether
- p-nonylphenyl polyethylene glycol ether
- polyoxyethylene (9) nonyl phenyl ether
- prelude
- prelude
- semicid
- tergitol np9
- tergitol np9
- tergitol np-9
- tergitol np-9
- today
- today
- today sponge
- today sponge
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06203080 | Phase 2 | Jan 1, 2024 | Government of China |
| NCT02693418 | Phase 1 | Aug 24, 2016 | Case Western Reserve University, Clinical Research Management, Inc., Evofem Inc., Johns Hopkins University |
| NCT02545452 | Phase 1 | Sep 1, 2015 | Bayer |
| NCT01593124 | Phase 2 | May 1, 2012 | CONRAD, Eastern Virginia Medical School |
| NCT01306331 | Phase 3 | Apr 1, 2011 | Evofem Inc., Health Decisions |
| NCT01232803 | Phase 1 | Oct 1, 2010 | CONRAD, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00389311 | Early Phase 1 (Phase 1) | Apr 1, 2007 | Johns Hopkins University |
| NCT00274261 | Phase 3 | Jun 1, 2004 | Health Decisions, National Institutes of Health (NIH) |
| NCT00692952 | Phase 2 | Mar 1, 2004 | Chang Jiang Bio-pharmaceutical Co., Ltd., Fudan University, Jiao Tong University, Shanghai Municipal Commission of Population and Family Planning |
| NCT00000926 | Phase 3 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000929 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 2 | 2 | 1999 |
| CONRAD | For profit | 2 | 2 | 2 | 2010 |
| Evofem Inc. | For profit | 2 | 2 | 2 | 2011 |
| Health Decisions | For profit | 2 | 1 | 1 | 2004 |
| Johns Hopkins University | Academic/Hospital | 2 | 1 | 1 | 2007 |
| Bayer | For profit | 1 | 1 | 1 | 2015 |
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Chang Jiang Bio-pharmaceutical Co., Ltd. | Government | 1 | 0 | 1 | 2004 |
| Clinical Research Management, Inc. | For profit | 1 | 0 | 1 | 2016 |
| Eastern Virginia Medical School | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2004 |
| Shanghai Municipal Commission of Population and Family Planning | Government | 1 | 0 | 1 | 2004 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Mayer Laboratories | For profit | NDA2 | Apr 1, 1983 |
| Personal Products | For profit | NDA2 | Dec 10, 1963 |
| Personal Products | For profit | NDA | Dec 10, 1963 |